Payment overview · 2025
General Payments
$390.17
19 reported records · 10 companies
Healthcare provider profile · identity verified
Nicholas Harman
Allopathic & Osteopathic Physicians|Family Medicine · BRISTOL, TN · NPI 1952641193
Verified facts
What the public records show
CMS Open Payments records show Nicholas Harman received $390.17 in general payments during 2025 across 19 reported records.
Lilly USA, LLC accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $108.78 | 27.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.51 | 17.8% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.53 | 13.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.65 | 8.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.73 | 7.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.66 | 6.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.06 | 5.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.48 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.18 | 3.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.59 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $390.17 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $108.78 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $88.77 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.65 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| OXLUMO Normalized: oxlumo |
Drug | Alnylam Pharmaceuticals Inc. | $25.77 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 25 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 745 | 177 |
| Omeprazole | Omeprazole | 744 | 173 |
| Lisinopril | Lisinopril | 658 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 619 | 153 |
| Levothyroxine Sodium | Levothyroxine Sodium | 574 | 128 |
| Tamsulosin Hcl | Tamsulosin Hcl | 415 | 95 |
| Montelukast Sodium | Montelukast Sodium | 397 | 86 |
| Losartan Potassium | Losartan Potassium | 383 | 105 |
| Meloxicam | Meloxicam | 372 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 367 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 364 | 95 |
| Metformin Hcl | Metformin Hcl | 364 | 90 |
| Furosemide | Furosemide | 361 | 99 |
| Gabapentin | Gabapentin | 318 | 70 |
| Simvastatin | Simvastatin | 295 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 285 | 68 |
| Prednisone | Prednisone | 255 | 155 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 64 |
| Eliquis | Apixaban | 239 | 48 |
| Warfarin Sodium | Warfarin Sodium | 235 | 23 |
| Potassium Chloride | Potassium Chloride | 226 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 217 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 64 |
| Trazodone Hcl | Trazodone Hcl | 192 | 48 |
| Carvedilol | Carvedilol | 182 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 42 |
| Allopurinol | Allopurinol | 169 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 158 | 36 |
| Atenolol | Atenolol | 156 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 37 |
| Glipizide Er | Glipizide | 137 | 38 |
| Metformin Hcl Er | Metformin Hcl | 136 | 34 |
| Famotidine | Famotidine | 132 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 127 | 38 |
| Azithromycin | Azithromycin | 123 | 101 |
| Ibuprofen | Ibuprofen | 120 | 47 |
| Sertraline Hcl | Sertraline Hcl | 117 | 29 |
| Finasteride | Finasteride | 116 | 24 |
| Lorazepam | Lorazepam | 115 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 105 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 104 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 21 |
| Tramadol Hcl | Tramadol Hcl | 99 | 24 |
| Clonazepam | Clonazepam | 97 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 96 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 28 |
| Januvia | Sitagliptin Phosphate | 90 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 87 | 74 |
| Celecoxib | Celecoxib | 79 | 22 |
| Donepezil Hcl | Donepezil Hcl | 79 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 79 | 16 |
| Alprazolam | Alprazolam | 78 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 61 |
| Alendronate Sodium | Alendronate Sodium | 76 | 15 |
| Ezetimibe | Ezetimibe | 76 | 23 |
| Pregabalin | Pregabalin | 74 | 16 |
| Ondansetron Odt | Ondansetron | 72 | 33 |
| Ozempic | Semaglutide | 72 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 17 |
| Fluconazole | Fluconazole | 66 | 39 |
| Enalapril Maleate | Enalapril Maleate | 65 | 17 |
| Synthroid | Levothyroxine Sodium | 62 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 14 |
| Glipizide | Glipizide | 56 | 16 |
| Ibu | Ibuprofen | 54 | 15 |
| Cefdinir | Cefdinir | 53 | 45 |
| Spironolactone | Spironolactone | 53 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 52 | 12 |
| Cephalexin | Cephalexin | 52 | 39 |
| Chlorthalidone | Chlorthalidone | 52 | 12 |
| Glimepiride | Glimepiride | 52 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 51 | suppressed |
| Methocarbamol | Methocarbamol | 51 | 13 |
| Sucralfate | Sucralfate | 51 | 14 |
| Buspirone Hcl | Buspirone Hcl | 50 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | suppressed |
| Dutasteride | Dutasteride | 47 | suppressed |
| Mirtazapine | Mirtazapine | 47 | 13 |
| Ramipril | Ramipril | 47 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 16 |
| Lansoprazole | Lansoprazole | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 17 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | 15 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Gemfibrozil | Gemfibrozil | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Nystatin | Nystatin | 40 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 11 |
| Mupirocin | Mupirocin | 33 | 21 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 27 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 20 |
| Levofloxacin | Levofloxacin | 31 | 26 |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Desloratadine | Desloratadine | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | 11 |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Desmopressin Acetate | Desmopressin Acetate | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | 18 |
| Nitroglycerin | Nitroglycerin | 21 | 13 |
| Temazepam | Temazepam | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Moexipril Hcl | Moexipril Hcl | 13 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $390.17 · 19 records | Lilly USA, LLC | AIRSUPRA, Auvelity, BREZTRI, Dexcom G6 Transmitter, FARXIGA, GIVLAARI, JARDIANCE, MOUNJARO, OXLUMO, Ozempic, PAXLOVID, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error